An observational study in We Aim to Examine the Predictors of Sustained Complete Renal Remission in Patients With Lupus Nephritis at Sohag University Hospital, sponsored by Sohag University. Status unknown at 1 site in Egypt. Open to participants aged 14 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-02-16.
Sponsored by Sohag University · Observational
Systemic lupus erythematosus (SLE) is an autoimmune disease which may give rise to multiple organ involvement because of immune complex deposits. Lupus nephritis (LN) is one of the severe manifestations of systemic lupus erythematous (SLE) and a common cause for end-stage renal disease, significantly affecting the survival of SLE patients Immunosuppressive treatment is the major therapy for active LN. Generally, at least six months are needed to assess treatment responses Failure to respond to immunosuppressive therapy can lead to a worsening of renal function
This study will be prospectively analyzing the clinical data of LN patients who received standard immunosuppressive therapy and were regularly followed up at our center for more than six months. These patients will not change treatment regimen during the six months.
As remission is an independent predictor of good long term prognosis in lupus nephritis. We aim to examine the predictors of sustained complete renal remission in patients with lupus nephritis at Sohag University Hospital and to analyze data of lupus nephritis patients to find parameters that can predict remission and improve outcome of our cases
245 studies on the registry are indexed under Nephritis; 56 are open to participants now.
This study's planned enrollment of 100 is above the median of 90 across 69 observational studies indexed under Nephritis.
Browse Nephritis studies →Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.
Counted across the registry records on this site, refreshed daily.
o Patients diagnosed with LN at Sohag University Hospital
o Patients diagnosed with LN at Sohag University Hospital
Exclusion Criteria:
o Patients with incomplete pathological data and the number of glomeruli being \<10 per biopsy specimen
follow up for treatment response
Also known as: indoxan
complete renal response
Alb _35 g/l, UPCR\<0.3 g/g, a normal range of sCr or at a level increasing no more than 15% from baseline and without lupus flares.
Time frame: 6 months
Plan to share: No — sharing final results only
No publications or documents are linked to this record.
This study is status unknown, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sohag University